Oslo, Norway, 12 May 2020: Photocure ASA ("Photocure" or the "Company") has on
12 May 2021 repurchased a total of 5,344 own shares. The shares were restricted
shares and are repurchased pursuant to the terms of the Company's long term
incentive program and due to the resignment of one of the former participants in
the incentive program.

The Company has repurchased the shares on the following terms:

  · 3,803 shares at a price per share of NOK 13.94 equal to 67% of share price
of NOK 20.81 per share on grant day 7 May 2018.
  · 1,541 shares at a price per share of NOK 0 per share equal to 0% of the
average volume weighted price of NOK 30.91 per share on grant day 13 May 2020.

After the acquisition, Photocure owns 21,010 own shares in the Company.

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.